According to Novocure
's latest financial reports the company has a price-to-book ratio of 3.66.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 4.40 | -74.78% |
2022-12-31 | 17.4 | -8.11% |
2021-12-31 | 19.0 | -48.63% |
2020-12-31 | 37.0 | -4.01% |
2019-12-31 | 38.5 | 38.47% |
2018-12-31 | 27.8 | 74.97% |
2017-12-31 | 15.9 | 232.14% |
2016-12-31 | 4.79 | -35.92% |
2015-12-31 | 7.47 | |
2014-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Organovo ONVO | 1.63 | -55.50% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | 4.74 | 29.29% | ๐ฌ๐ง UK |
Novavax NVAX | -0.8101 | -122.12% | ๐บ๐ธ USA |
Novocure
NVCR | 3.66 | 0.00% | Jersey |